Insider Transactions in Q1 2025 at Kala Pharmaceuticals, Inc. (KALA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2025
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,706
-2.43%
|
$11,942
$7.63 P/Share
|
|
Jan 06
2025
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,100
+12.56%
|
-
|
|
Jan 06
2025
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,779
-2.02%
|
$40,453
$7.63 P/Share
|
|
Jan 06
2025
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,100
+7.18%
|
-
|
|
Jan 06
2025
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
2,446
-2.58%
|
$17,122
$7.63 P/Share
|
|
Jan 06
2025
|
Romulus K Brazzell |
BUY
Grant, award, or other acquisition
|
Direct |
10,100
+9.62%
|
-
|
|
Jan 06
2025
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
1,993
-2.14%
|
$13,951
$7.63 P/Share
|
|
Jan 06
2025
|
Todd Bazemore |
BUY
Grant, award, or other acquisition
|
Direct |
10,100
+9.78%
|
-
|
|
Jan 06
2025
|
Darius Kharabi CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
2,021
-2.89%
|
$14,147
$7.63 P/Share
|
|
Jan 06
2025
|
Darius Kharabi CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,100
+12.64%
|
-
|